NIMS' Exer-Rest Medical Device Provides "Passive Exercise" to Aid Patients with Circulatory Health Concerns

Press releases may be edited for formatting or style | November 02, 2010

Exer-Rest is marketed in the U.S. as an aid to temporarily increase local circulation, provide temporary relief of minor aches and pains, reduce morning stiffness and provide local muscle relaxation. Exer-Rest is FDA listed as a Class I Exempt Medical Device, and carries the international CE mark of Class IIa Medical Device. Exer-Rest is available for sale in the U.S., Canada, Mexico, EU, UK and other major markets.

About NIMS

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

Founded in 1978, Non-Invasive Monitoring Systems, Inc. is a medical device company committed to discovering, developing and marketing innovative non-invasive, evidence-based products that improve the health and quality of life of patients who have highly debilitating medical conditions, while also meeting the medical needs of the healthcare professionals who treat them.

NIMS introduced "Whole Body Periodic Acceleration (WBPA)," a therapy based on their patented "Acceleration Therapeutics® (AT)" technology, to the market through its flagship product Exer-Rest®.

For more information about NIMS and its Exer-Rest products, please visit www.nims-inc.com, email info@nims-inc.com or call 305-575-4200.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA). Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks and uncertainties associated with any claimed benefits derived from the Exer-Rest, obtaining regulatory approvals in the U.S. and other countries, establishing marketing, sales and distribution activities in the U.S. and other countries, the uncertainty of future financial results, additional financing requirements, development of new products by us or our competitors, government approval processes, technological changes, and other uncertainties. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Back to HCB News